
### [MONDO:0007893](http://purl.obolibrary.org/obo/MONDO_0007893)
**Label:** Noonan syndrome with multiple lentigines

**Subclasses:** [MONDO:0012691](http://purl.obolibrary.org/obo/MONDO_0012691) (leopard syndrome 2), [MONDO:0013380](http://purl.obolibrary.org/obo/MONDO_0013380) (leopard syndrome 3), 

**Mapped go classes:** [GO:0007275](http://purl.obolibrary.org/obo/GO_0007275) (multicellular organism development), [GO:0005057](http://purl.obolibrary.org/obo/GO_0005057) (signal transducer activity, downstream of receptor), [GO:0006468](http://purl.obolibrary.org/obo/GO_0006468) (protein phosphorylation), [GO:0000166](http://purl.obolibrary.org/obo/GO_0000166) (nucleotide binding), [GO:0005524](http://purl.obolibrary.org/obo/GO_0005524) (ATP binding), [GO:0007507](http://purl.obolibrary.org/obo/GO_0007507) (heart development), [GO:0000186](http://purl.obolibrary.org/obo/GO_0000186) (activation of MAPKK activity), [GO:0009968](http://purl.obolibrary.org/obo/GO_0009968) (negative regulation of signal transduction), [GO:0005829](http://purl.obolibrary.org/obo/GO_0005829) (cytosol), [GO:0016310](http://purl.obolibrary.org/obo/GO_0016310) (phosphorylation), [GO:0035556](http://purl.obolibrary.org/obo/GO_0035556) (intracellular signal transduction), [GO:0031434](http://purl.obolibrary.org/obo/GO_0031434) (mitogen-activated protein kinase kinase binding), [GO:0007165](http://purl.obolibrary.org/obo/GO_0007165) (signal transduction), [GO:0004672](http://purl.obolibrary.org/obo/GO_0004672) (protein kinase activity), [GO:0004674](http://purl.obolibrary.org/obo/GO_0004674) (protein serine/threonine kinase activity), [GO:0005886](http://purl.obolibrary.org/obo/GO_0005886) (plasma membrane), [GO:0005622](http://purl.obolibrary.org/obo/GO_0005622) (intracellular), [GO:0046872](http://purl.obolibrary.org/obo/GO_0046872) (metal ion binding), [GO:0043066](http://purl.obolibrary.org/obo/GO_0043066) (negative regulation of apoptotic process), [GO:0070374](http://purl.obolibrary.org/obo/GO_0070374) (positive regulation of ERK1 and ERK2 cascade), [GO:0016020](http://purl.obolibrary.org/obo/GO_0016020) (membrane), [GO:0030154](http://purl.obolibrary.org/obo/GO_0030154) (cell differentiation), [GO:0016021](http://purl.obolibrary.org/obo/GO_0016021) (integral component of membrane), [GO:0004709](http://purl.obolibrary.org/obo/GO_0004709) (MAP kinase kinase kinase activity), [GO:0016740](http://purl.obolibrary.org/obo/GO_0016740) (transferase activity), [GO:0016301](http://purl.obolibrary.org/obo/GO_0016301) (kinase activity), 

**Class expressions from DL-Learner:**

- [GO:0031434](http://purl.obolibrary.org/obo/GO_0031434) (mitogen-activated protein kinase kinase binding) 66.67%
- [GO:0005622](http://purl.obolibrary.org/obo/GO_0005622) (intracellular) 66.67%
- [GO:0005524](http://purl.obolibrary.org/obo/GO_0005524) (ATP binding) 66.67%
- [GO:0032559](http://purl.obolibrary.org/obo/GO_0032559) (adenyl ribonucleotide binding) and [GO:0035639](http://purl.obolibrary.org/obo/GO_0035639) (purine ribonucleoside triphosphate binding) 66.67%
- [GO:0030554](http://purl.obolibrary.org/obo/GO_0030554) (adenyl nucleotide binding) and [GO:0035639](http://purl.obolibrary.org/obo/GO_0035639) (purine ribonucleoside triphosphate binding) 66.67%
- [GO:0008144](http://purl.obolibrary.org/obo/GO_0008144) (drug binding) and [GO:0035639](http://purl.obolibrary.org/obo/GO_0035639) (purine ribonucleoside triphosphate binding) 66.67%
- [GO:0030554](http://purl.obolibrary.org/obo/GO_0030554) (adenyl nucleotide binding) and [GO:0035639](http://purl.obolibrary.org/obo/GO_0035639) (purine ribonucleoside triphosphate binding) and [GO:0097367](http://purl.obolibrary.org/obo/GO_0097367) (carbohydrate derivative binding) 66.67%
- [GO:0030554](http://purl.obolibrary.org/obo/GO_0030554) (adenyl nucleotide binding) and [GO:0032555](http://purl.obolibrary.org/obo/GO_0032555) (purine ribonucleotide binding) and [GO:0035639](http://purl.obolibrary.org/obo/GO_0035639) (purine ribonucleoside triphosphate binding) 66.67%
- [GO:0030554](http://purl.obolibrary.org/obo/GO_0030554) (adenyl nucleotide binding) and [GO:0032553](http://purl.obolibrary.org/obo/GO_0032553) (ribonucleotide binding) and [GO:0035639](http://purl.obolibrary.org/obo/GO_0035639) (purine ribonucleoside triphosphate binding) 66.67%
- [GO:0008144](http://purl.obolibrary.org/obo/GO_0008144) (drug binding) and [GO:0035639](http://purl.obolibrary.org/obo/GO_0035639) (purine ribonucleoside triphosphate binding) and [GO:0097367](http://purl.obolibrary.org/obo/GO_0097367) (carbohydrate derivative binding) 66.67%
- [GO:0008144](http://purl.obolibrary.org/obo/GO_0008144) (drug binding) and [GO:0035639](http://purl.obolibrary.org/obo/GO_0035639) (purine ribonucleoside triphosphate binding) and [GO:0036094](http://purl.obolibrary.org/obo/GO_0036094) (small molecule binding) 66.67%
- [GO:0008144](http://purl.obolibrary.org/obo/GO_0008144) (drug binding) and [GO:0032559](http://purl.obolibrary.org/obo/GO_0032559) (adenyl ribonucleotide binding) and [GO:0035639](http://purl.obolibrary.org/obo/GO_0035639) (purine ribonucleoside triphosphate binding) 66.67%
- [GO:0008144](http://purl.obolibrary.org/obo/GO_0008144) (drug binding) and [GO:0032555](http://purl.obolibrary.org/obo/GO_0032555) (purine ribonucleotide binding) and [GO:0035639](http://purl.obolibrary.org/obo/GO_0035639) (purine ribonucleoside triphosphate binding) 66.67%
- [GO:0008144](http://purl.obolibrary.org/obo/GO_0008144) (drug binding) and [GO:0032553](http://purl.obolibrary.org/obo/GO_0032553) (ribonucleotide binding) and [GO:0035639](http://purl.obolibrary.org/obo/GO_0035639) (purine ribonucleoside triphosphate binding) 66.67%
- [GO:0008144](http://purl.obolibrary.org/obo/GO_0008144) (drug binding) and [GO:0030554](http://purl.obolibrary.org/obo/GO_0030554) (adenyl nucleotide binding) and [GO:0035639](http://purl.obolibrary.org/obo/GO_0035639) (purine ribonucleoside triphosphate binding) 66.67%


